Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own2.30% Shs Outstand335.97M Perf Week13.15%
Market Cap44.08B Forward P/E13.73 EPS next Y9.56 Insider Trans6.98% Shs Float325.68M Perf Month11.85%
Income-746.30M PEG- EPS next Q1.97 Inst Own66.80% Short Float3.83% Perf Quarter4.48%
Sales7.53B P/S5.85 EPS this Y-610.50% Inst Trans21.07% Short Ratio4.93 Perf Half Y-1.54%
Book/sh15.68 P/B8.37 EPS next Y19.43% ROA-2.70% Target Price52.38 Perf Year25.75%
Cash/sh1.58 P/C82.98 EPS next 5Y17.64% ROE-14.60% 52W Range102.60 - 153.10 Perf YTD11.75%
Dividend- P/FCF44.95 EPS past 5Y-33.00% ROI-0.10% 52W High-14.30% Beta0.91
Dividend %- Quick Ratio1.70 Sales past 5Y50.10% Gross Margin68.00% 52W Low27.88% ATR3.52
Employees17200 Current Ratio2.10 Sales Q/Q86.30% Oper. Margin16.10% RSI (14)70.32 Volatility4.02% 2.65%
OptionableYes Debt/Eq3.30 EPS Q/Q1064.80% Profit Margin-9.90% Rel Volume0.92 Prev Close130.26
ShortableYes LT Debt/Eq3.24 EarningsMay 08 BMO Payout- Avg Volume2.53M Price131.20
Recom3.00 SMA208.20% SMA5011.06% SMA2003.58% Volume2,320,900 Change0.72%
28-Feb-14Reiterated UBS Buy $141 → $170
28-Feb-14Reiterated RBC Capital Mkts Outperform $151 → $158
27-Feb-14Reiterated Aegis Capital Buy $160 → $180
08-Jan-14Reiterated UBS Buy $125 → $141
08-Jan-14Reiterated Ladenburg Thalmann Buy $123 → $155
08-Jan-14Reiterated FBR Capital Outperform $130 → $153
03-Dec-13Reiterated UBS Buy $115 → $125
01-Nov-13Reiterated Ladenburg Thalmann Buy $127 → $123
30-Oct-13Initiated FBR Capital Outperform $130
07-Oct-13Reiterated CRT Capital Buy $110 → $130
08-Aug-13Reiterated UBS Buy $96 → $115
07-Aug-13Reiterated Aegis Capital Buy $135 → $140
02-Jul-13Reiterated RBC Capital Mkts Outperform $76 → $100
10-Jun-13Upgrade CRT Capital Hold → Buy $100
29-May-13Reiterated Ladenburg Thalmann Buy $84 → $124
29-May-13Reiterated Deutsche Bank Buy $82 → $103
03-May-13Reiterated Deutsche Bank Buy $80 → $82
04-Apr-13Reiterated UBS Buy $83 → $81
04-Apr-13Reiterated RBC Capital Mkts Outperform $80 → $76
21-Mar-13Reiterated Deutsche Bank Buy $77 → $83
01-Oct-14 05:04AM  Ackman Fund Raises More Than $3 Billion in Amsterdam I.P.O. at New York Times
30-Sep-14 11:27AM  Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA PR Newswire
11:27AM  Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA CNW Group
11:10AM  Valeant's Bausch + Lomb Announces Results on Lotemax Zacks
29-Sep-14 06:32PM  Large-Cap Tech, Biotech Names Hang Tough In Shaky Market at Investor's Business Daily
06:32PM  Large-Cap Tech Names Hang Tough In Shaky Market at Investor's Business Daily
01:32PM  Rebound Efforts Fade For Stocks; Synchronoss Clears Resistance at Investor's Business Daily
01:03PM  Today's Stocks Driving Success For The Drugs Industry at TheStreet
12:34PM  Where the Allergan-Valeant(-Salix-Actavis-Teva) Fights Stand Now at The Wall Street Journal
08:30AM  3 Likely Biotech Buyout Candidates at 24/7 Wall St.
28-Sep-14 11:23AM  Drugs groups trapped in tangled M&A web at Financial Times
11:05AM  Jackson Square Partners Joins Investors Opposing Allergan Bid for Salix Benzinga
27-Sep-14 04:26PM  Major Allergan Investor Joins Chorus Against Salix Deal at New York Times
26-Sep-14 04:52PM  Why Allergan (AGN) Stock Is Declining in After-Hours Trading Today at TheStreet
04:16PM  T. Rowe joins concerns over Allergan governance at CNBC
04:00PM  Allergan Writes Back, Coaxes Shareholders Against Valeant Zacks
03:38PM  T. Rowe Price urges Allergan to drop Salix bid at MarketWatch
02:40PM  T.Rowe Calls For Shareholder Vote On Allergan's Plans Too at Barrons.com
11:50AM  Pentwater Comes Out Swinging Against Allergan Board, Possible Salix Deal at Barrons.com
08:02AM  Meet 5 Top Stocks With Rising Earnings Estimates at Investor's Business Daily
08:00AM  Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% PR Newswire
08:00AM  Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% CNW Group
25-Sep-14 05:39PM  Today's Market Thorns, Roses, and All Time Highs... Plus an Extra... Yahoo Finance Blogs
05:32PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Even EDGAR Online
03:40PM  Valeant (VRX) Sends Letter to Allergan, Provides Q3 Update Zacks
02:40PM  Midday movers: Apple, GameStop, H.B. Fuller & more at CNBC
02:13PM  Midday movers: Apple, GameStop, H.B. Fuller & more at CNBC
01:47PM  Valeant: Glaucoma Drug Is Potential Blockbuster at Investor's Business Daily
01:34PM  Midday movers: Apple, GameStop, H.B. Fuller & more at CNBC
01:25PM  Valeant/Allergan: stand by me at Financial Times
01:01PM  ValueAct's Ubben To Join Valeant's Board; Valeant Shares Rise 3% at Barrons.com
11:39AM  ValueAct is Back in Valeant's Board Room, Expects to Buy More Shares at The Wall Street Journal
11:34AM  Apple Fuels Tech Sell-Off; Valeant Bucks The Trend at Investor's Business Daily
10:18AM  Canada Stocks to Watch: BlackBerry, Vecima, Valeant and Finning at The Wall Street Journal
08:28AM  Valeant pitches potential eye drug, research focus AP
08:15AM  Valeant Names ValueActs Ubben to Board of Directors at Bloomberg
08:00AM  Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals PR Newswire
08:00AM  Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals CNW Group
07:54AM  Valeant Pharmaceuticals (VRX) in Focus: Stock Adds 6.9% Zacks
02:12AM  Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO(R) (latanoprostene bunod) GlobeNewswire
02:00AM  Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO┬« (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies PR Newswire
02:00AM  Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO┬« (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies CNW Group
24-Sep-14 05:49PM  Valeant Grows Bullish On Q3 Sales While Allergan's Defense Weakens Investor's Business Daily +6.94%
05:40PM  Allergan, Inc. -- Moody's reviews Allergan's ratings for downgrade at Moody's
05:16PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:49PM  Acorda and GrafTech are big market movers AP
04:23PM  Valeant Ends Prince Charming Act; Allergan Hopes Rise at Investor's Business Daily
03:55PM  Valeant Ends Prince Charming Act; Allergan Hopes Rise at Investor's Business Daily
03:45PM  Allergan and Salix Pharmaceuticals Up on Takeover Rumors Zacks
03:07PM  Valeant Shares Vault Higher, Boosting Allergan Bid Again at The Wall Street Journal
12:06PM  Valeant Switches to Sugar, but Allergan Still Not Biting at New York Times
11:51AM  Actavis reportedly in talks to buy Salix Pharma at MarketWatch
11:42AM  Midday movers: Hasbro, KB Home, Transocean & more at CNBC
11:22AM  Bed Bath, Starz gain; Citizens Financial debuts at MarketWatch
09:56AM  Valeant offers olive branch to Allergan at MarketWatch
09:05AM  Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director CNW Group
09:01AM  Faber: Actavis pursues Salix CNBC
23-Sep-14 04:37PM  Pfizer Said to Have Approached Actavis About Takeover to Lower Tax Rate Bloomberg
02:11PM  Pfizer Said to Approach Actavis to Gauge Interest in Deal at Bloomberg
12:51PM  Bill Ackman's Big Takeover Deal May Be Spinning Out Of His Hands, And He's Threatening To Sue Business Insider
12:49PM  Midday movers: AbbVie, Burger King, CarMax & more at CNBC
11:56AM  Stocks Fall Modestly; New Issue Alibaba Extends Losses at Investor's Business Daily
11:47AM  Video: Allergan-Ackman War Reignites On Salix Rumors at Investor's Business Daily
11:47AM  Allergan-Ackman Flame War Reignites On Salix Rumors at Investor's Business Daily
11:29AM  [video] Pershing Square Warns Allergan on Salix at MarketWatch
10:56AM  Indexes Pare Losses As Salix Soars On Buyout Talk at Investor's Business Daily
10:10AM  Shareholders Must Vote On Allergan-Salix Deal, Threatens Ackman at Barrons.com
09:14AM  Salix & Allergan in serious talks CNBC
09:14AM  [video] Salix & Allergan in serious talks at CNBC
08:55AM  Stock Futures Lower, But Salix Soars On Buyout Talk at Investor's Business Daily
08:26AM  Ackman Threatens to Sue if Allergan Proceeds With Salix Deal at New York Times
22-Sep-14 08:06PM  Obama Administration Moves To Try To Stop Companies From Leaving America at Forbes
08:06PM  Obama Administration Moves To Try Stop Companies From Leaving America at Forbes
06:56PM  Botox Maker Allergan Said to Be in Talks to Acquire Salix at New York Times
19-Sep-14 01:04PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Financials EDGAR Online Financials
18-Sep-14 05:01PM  Must-know: Eminence Capital sells its stake in Valmont Industries Market Realist
04:05PM  Allergan-Valeant Fight Holds Lessons for All Corporate Shareholders at New York Times
01:19PM  Valeant's Improving Stock Price Makes its Allergan Bid Look Better at The Wall Street Journal
01:01PM  Must-know: Eminence Capital exits a position in Qualcomm Market Realist
09:00AM  Must-know: Eminence Capital starts a new position in Baidu Market Realist
17-Sep-14 05:23PM  Eminence Capital has a new position in Valeant Pharmaceuticals Market Realist
05:00PM  Steven Cohens Point72 Asset Management cuts its stake in Baidu Market Realist
01:23PM  Eminence Capital adds a new position in Madison Square Garden Market Realist
01:00PM  Point72 Asset Management reduces a large stake in Yahoo Market Realist
12:04PM  Valeants Last Shot to Woo Owners of Botox Maker Allergan at New York Times
09:22AM  Overview: Eminence Capitals key 2Q14 positions Market Realist
16-Sep-14 05:00PM  Point72 ups its position in Valeant Pharmaceuticals in 2Q14 Market Realist
01:00PM  Point72 Asset Management increases its stake in Whiting Petroleum Market Realist
11:57AM  Allergan, Pershing Square Settle: Now What? at Barrons.com
11:36AM  Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
11:36AM  Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
09:42AM  Faber Report: Allergan special meeting CNBC
09:00AM  Point72 Asset Management adds to its position in Baker Hughes Market Realist
08:34AM  Tigers Chopra Stumbles in Rise to Top Robertson Empire Bloomberg
07:18AM  Allergan agrees to move forward with meeting AP
06:35AM  Allergan agrees to move forward with meeting AP
12:57AM  Botox Maker Allergan Agrees to Hold Meeting That Could Lead to Takeover at New York Times
12:57AM  Allergan Agrees to Hold Meeting That Could Lead to Takeover at New York Times
15-Sep-14 08:03PM  Tigers Chopra Stumbles in Rise to Top Robertson Empire at Bloomberg
05:00PM  Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 PR Newswire
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM
Weldon RyanEVP, Company Group ChairmanJan 24Option Exercise0.0019,0000101,539Jan 28 05:09 PM
Mirovsky PavelPresident of Valeant EuropeJan 24Option Exercise0.0010,000010,000Jan 28 05:00 PM
Kornwasser LaizerEVP, Company Group ChairmanJan 24Buy132.152,536335,12828,390Jan 28 04:51 PM
Stolz Brian M.EVP, Administration and CHCOJan 20Option Exercise0.0045,000077,939Jan 22 04:55 PM